Hospital Drug Payment Restrictions: When the Manufacturer’s Rebate Agreement Changes the Bill

Hospital Medicare Part B drug payment depends on the manufacturer’s effective Medicaid rebate agreement for covered outpatient drugs. The product used, the code billed and the service date belong together. If you work in hospital pharmacy or billing and saw a payment restriction overridden, you may know who connected those facts and who decided to send the claim anyway. That decision is where a public payment rule becomes a question about hospital billing fraud.

What the Manufacturer’s Medicaid Rebate Agreement Changes

The Centers for Medicare & Medicaid Services requires the manufacturer to have an effective Medicaid National Drug Rebate Agreement before Medicare Part B can pay for its covered outpatient drugs. Its final hospital outpatient payment rule, published November 25, 2025, set April 1, 2026 as the stop date for payment on the affected product codes whose manufacturers remained out of compliance. The requirement reaches drugs, biologicals and radiopharmaceuticals that meet the covered outpatient drug definition.

The restriction operates through the HCPCS billing code describing the product. The agency assigned affected codes the outpatient status indicator E1, meaning Medicare does not pay when they appear on outpatient claims. For a hospital reimbursement employee, the manufacturer’s agreement can therefore determine whether the drug line is payable at all.

That question comes before the familiar calculation of how much Medicare pays. The Medicare Payment Advisory Commission describes separately payable outpatient drugs as paid at average sales price plus 6 percent. A pharmacy’s acquisition cost, a drug’s payment rate and the manufacturer’s eligibility for payment answer different parts of the same transaction.

When Medicare Drug Payment Stops and Restarts

A drug’s payment status can change when its manufacturer enters the rebate agreement. The agency says payment resumes retroactively to the date it receives and accepts the signed, completed agreement. That date matters when we compare a hospital claim with the restriction in effect for the care it describes.

The final rule already showed movement. The agency said three manufacturers listed in its proposed rule had come into compliance, and it designated their affected products for separate outpatient payment. It also said it would identify drugs unpaid because of the missing agreement in its average sales price files and outpatient payment list, Addendum B.

The agency described the rebate agreement as an existing requirement, not a new condition created by the final rule. It said manufacturers had received notices in the spring of 2025 and through the proposed rule, and rejected requests for another postponement. For a particular hospital claim, we connect the product and code to the payment file applicable to its service date, including any effective reinstatement.

One Manufacturer Can Affect Several Products

The manufacturer’s agreement can determine payment for more than the product that first draws a billing employee’s attention. In the final rule, the agency answered a request from Vericel for separate outpatient payment for MACI under code J7330, which describes autologous cultured chondrocytes for implantation. It pointed to another Vericel product, anacaulase-bcdb gel under J7353, and said its records showed no active rebate agreement for the manufacturer at that time.

The agency’s answer applied to all of Vericel’s covered outpatient drugs. It said none could receive Part B payment while the manufacturer lacked the agreement. For an insider, that makes manufacturer identity part of the claim review: a discussion confined to one product’s coding can miss the payment condition shared across the manufacturer’s products.

The Part B Condition and the Hospital’s 340B Discount

The 340B rules on diversion and duplicate discounts govern who can receive discounted drugs and whether the same drug also generates a Medicaid rebate. Hospital drug margins arise from the difference between the discounted purchase price and reimbursement. The manufacturer’s effective rebate agreement answers the separate question of whether Medicare Part B can pay for its covered outpatient drug.

MemorialCare paid $31,532,679 to settle allegations of Medi-Cal drug overbilling. In its 2020 settlement announcement, the Justice Department’s U.S. Attorney’s Office for the Central District of California alleged that MemorialCare kept billing at usual costs after a court lifted a temporary block on California’s requirement to bill at actual acquisition cost. The useful parallel is the hospital’s response when a payment condition changes. Someone inside may know why the old billing treatment continued.

How a Nonpayable Drug Could Reach a Paid Hospital Claim

In health care billing, the useful comparison follows the drug actually used into the claim Medicare received. For a pharmacy insider, we would start with the purchasing, dispensing or administration record that identifies the product and manufacturer. For a charge-capture or reimbursement insider, the corresponding question is which HCPCS code reached the bill and why that code was selected.

A claim edit, an exception record or an instruction to change the code may explain how the hospital handled the restriction. We connect that decision to the manufacturer’s agreement status on the service date and the payment Medicare actually made. The concern is government money paid on a claim that misdescribes the drug.

The 2023 study Types of Hospital Frauds: Nature and Methods of Prevention, published in the Journal of Forensic and Investigative Accounting, identified comparing billing records with medical records and analyzing unusual coding patterns as ways to detect hospital billing schemes. It found that timing and location were important in the cases where coding analysis could have helped. We apply that comparison here to the administered product, the billed code and the date-specific payment condition.

If you saw staff substitute a different code after a restriction appeared, the explanation for that substitution matters. We would compare what the replacement code described with what pharmacy actually supplied, then trace the instruction and the claims it affected. An insider can explain the choice behind a number that otherwise looks like another line on a bill.

Who Knew Why the Claim Went Through?

For a hospital False Claims Act case, we want to know who understood the drug was not payable and what they told Medicare to get it paid. In this setting, an insider’s account can connect the product, the dated restriction, an internal warning and the decision to keep billing. We want to understand who saw the restriction, what they were told and what changed on the next claim.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Your knowledge of the billing decision can connect the payment restriction to the people who chose how the hospital would respond.

When You Know Why the Edit Was Overridden

If your healthcare job involves pharmacy, reimbursement or compliance and you saw how a restricted drug became a paid claim, speak with our whistleblower experts about that billing decision. We work beside you to connect the manufacturer’s payment status with the hospital’s records and build the strongest case those facts support. We bring in hospital fraud whistleblower lawyers who know drug billing and stay beside you through the case.